Molecular Partners has outlined its clinical expansion plans and strengthened its strategic focus on radiopharma for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference. A significant part of this plan includes the Radio-DARPin MP0712 against DLL3, developed in collaboration with Orano Med, which is set to enter its first-in-human study in 2025. Additionally, Mesothelin has been named as the second target in the Radio-DARPin pipeline, with a program to be co-developed with Orano Med.
The expanded partnership between Molecular Partners and Orano Med is aimed at fueling a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, increasing the total number of programs up to ten. This collaboration highlights the commitment of both companies to advancing cancer therapy through targeted alpha radio-therapies, leveraging their combined expertise and resources to bring innovative treatments to patients.
